Malignant Neoplasm Clinical Trials in Chengdu, Sichuan
3 recruitingChengdu, Sichuan, China
Showing 1–3 of 3 trials
Recruiting
Phase 2
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Malignant Neoplasm
Merck Sharp & Dohme LLC130 enrolled21 locationsNCT07252739
Recruiting
Phase 1Phase 2
A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
Malignant Neoplasm
Tyligand Pharmaceuticals (Suzhou) Limited440 enrolled19 locationsNCT06385925
Recruiting
Phase 1Phase 2
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Advanced Solid TumorsMalignant Neoplasm
Merck Sharp & Dohme LLC270 enrolled42 locationsNCT06818643